(Q51913689)

17 April 2018

title

Plasma concentrations of mycophenolic acid acyl glucuronide are not associated with diarrhea in renal transplant recipients. (English)

1 reference

17 April 2018

0 references

T Heller

1

1 reference

17 April 2018

T van Gelder

2

1 reference

17 April 2018

K Budde

3

1 reference

17 April 2018

J W de Fijter

4

1 reference

17 April 2018

D Kuypers

5

1 reference

17 April 2018

W Arns

6

1 reference

17 April 2018

J Schmidt

7

1 reference

17 April 2018

L Rostaing

8

1 reference

17 April 2018

S H Powis

9

1 reference

17 April 2018

K Claesson

10

1 reference

17 April 2018

I A M Macphee

11

1 reference

17 April 2018

E Pohanka

12

1 reference

17 April 2018

J Engelmayer

13

1 reference

17 April 2018

G Brandhorst

14

1 reference

17 April 2018

M Oellerich

15

1 reference

17 April 2018

V W Armstrong

16

1 reference

17 April 2018

language of work or name

English

0 references

publication date

26 May 2007

1 reference

17 April 2018

American Journal of Transplantation

published in

1 reference

17 April 2018

volume

7

1 reference

17 April 2018

issue

7

1 reference

17 April 2018

page(s)

1822-1831

1 reference

17 April 2018

Immunosuppression: evolution in practice and trends, 1994-2004.

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2007.01859.X

Intravenous mycophenolate mofetil: safety, tolerability, and pharmacokinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2007.01859.X

Therapeutic equivalence of mycophenolate sodium versus mycophenolate mofetil in de novo renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2007.01859.X

Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2007.01859.X

Mycophenolate sodium does not reduce the incidence of GI adverse events compared with mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2007.01859.X

Mycophenolic Acid Pharmacodynamics and Pharmacokinetics Provide a Basis for Rational Monitoring Strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2007.01859.X

Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2007.01859.X

Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2007.01859.X

The acyl glucuronide metabolite of mycophenolic acid inhibits the proliferation of human mononuclear leukocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2007.01859.X

Acyl glucuronide drug metabolites: toxicological and analytical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2007.01859.X

Acyl glucuronide reactivity in perspective: biological consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2007.01859.X

Therapeutic drug monitoring of mycophenolate mofetil in transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2007.01859.X

Quantification by liquid chromatography tandem mass spectrometry of mycophenolic acid and its phenol and acyl glucuronide metabolites.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2007.01859.X

Dose optimization of mycophenolate mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2007.01859.X

Gastrointestinal complications in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2007.01859.X

Erosive enterocolitis in mycophenolate mofetil-treated renal-transplant recipients with persistent afebrile diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2007.01859.X

A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2007.01859.X

A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2007.01859.X

Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2007.01859.X

Cytochrome P450 3A4 and P-glycoprotein activity and assimilation of tacrolimus in transplant patients with persistent diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2007.01859.X

Intestinal tract injury by drugs: Importance of metabolite delivery by yellow bile road

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2007.01859.X

Pharmacokinetics and protein adduct formation of the pharmacologically active acyl glucuronide metabolite of mycophenolic acid in pediatric renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2007.01859.X

Identification of protein targets for mycophenolic acid acyl glucuronide in rat liver and colon tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2007.01859.X

Within-patient variability of mycophenolic acid exposure: therapeutic drug monitoring from a clinical point of view.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2007.01859.X

Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistance-associated protein 2 in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2007.01859.X

Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2007.01859.X

Role of Mrp2 in the hepatic disposition of mycophenolic acid and its glucuronide metabolites: effect of cyclosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2007.01859.X

Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2007.01859.X

A BLINDED, RANDOMIZED CLINICAL TRIAL OF MYCOPHENOLATE MOFETIL FOR THE PREVENTION OF ACUTE REJECTION IN CADAVERIC RENAL TRANSPLANTATION1

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2007.01859.X

10.1111/J.1600-6143.2007.01859.X

21 January 2018

Identifiers

DOI

1 reference

17 April 2018

1 reference

17 April 2018